reports
- Si Yong Ng
- Felix Fischer
- Haidje Rustau
- Jayanth Kandalam
- Si Yong Ng
- Tanvi Arora
Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia...
Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaignTD is a chronic movement disorder impacting one in four people who take certain prescription mental health medications. While TD can impact your daily life, it can be treated without interrupting your mental health treatment1-4Younger individuals, men, and racial and ethnic minority groups have lower rates of formal diagnoses despite the hig...
Teva to Present at UBS Global Healthcare Conference and Jefferies Lond...
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in November as follows: UBS Global Healthcare ConferenceMonday, November 10, 2025, at 8:45 A.M. Eastern Time (ET) Jefferies London Healthcare ConferenceTuesday, November 18, 2025, at 11:00 A.M. Greenwich Mean Time (6:00 A.M. ET) To access a live webcast ...
Teva und Prestige Biopharma schließen Lizenzvereinbarung für die Verma...
Teva und Prestige Biopharma schließen Lizenzvereinbarung für die Vermarktung von Tuznue® in Europa Teva und Prestige geben eine Lizenz- und Liefervereinbarung für die Vermarktung des von Prestige hergestellten Arzneimittels Tuznue® bekannt, einem Biosimilar zu Herceptin® (trastuzumab)Die Europäische Kommission (EK) erteilte Tuznue® im September 2024 die MarktzulassungDie Partnerschaft vereint das Know-how beider Unternehmen im Bereich Biosimilars TEL AVIV, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, eine Tochtergesellschaft von Teva Pharmaceutical I...
Teva et Prestige Biopharma concluent un accord de licence pour la comm...
Teva et Prestige Biopharma concluent un accord de licence pour la commercialisation de Tuznue® en Europe Teva et Prestige annoncent un accord de licence et d’approvisionnement pour la commercialisation de Tuznue®, un biosimilaire d’Herceptin® (trastuzumab) produit par PrestigeTuznue® a reçu l’autorisation de mise sur le marché de la Commission européenne (CE) en septembre 2024Ce partenariat conjugue l’expertise des deux entreprises dans le domaine des biosimilaires TEL AVIV, Israël, 21 oct. 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, une filiale de Teva Pharmaceutic...
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commer...
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue®, a biosimilar to Herceptin® (trastuzumab) Tuznue® received European Commission (EC) marketing authorization in September 2024Partnership brings together both companies’ expertise in biosimilars TEL AVIV, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) entered into a license agreement w...
- Felix Fischer
- Felix Fischer
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Rel...
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.1UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults.1This approval marks a significant step towards addr...
Teva Releases Q3 2025 Aide Memoire
Teva Releases Q3 2025 Aide Memoire TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the “Investors” page on its website. Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovativ...
Teva to Host Conference Call to Discuss Third Quarter 2025 Financial R...
Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025 TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial results on Wednesday, November 5, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance to obtain a local or toll-free phone number and your per...
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablet...
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine) extended-release tabletsPatients reported high satisfaction (>89%) with AUSTEDO XR, with 96% expressing interest in continuing treatmentAlmost all (>96%) patients relayed that AUSTEDO XR was easy to take PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliat...
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Sup...
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic safety profile was consistent with other olanzapine formulations1Additional new data comparing initiation of UZEDY® (risperidone) versus Invega Sustenna® (paliperidone palmitate) in hospit...
Teva to Host Conference Call to Discuss Data from the Completed Phase ...
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California. Teva will also host a conference call for analysts and investors on Monday, September 2...
- Si Yong Ng
- Felix Fischer
- Haidje Rustau
- Jayanth Kandalam
- Peter Low
- Si Yong Ng
- Tanvi Arora
Lucror Analytics - Morning Views Europe
In today's Morning Views publication we comment on developments of the following high yield issuers: Mahle, Guala Closures, Playtech, Grupo Antolin, NewDay, Kiloutou, David Lloyd Leisure, Omnia Technologies, Cirsa, evoke, Derichebourg, Seche Environnement, Samvardhana Motherson, Teva
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatmen...
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development.New therapeutic options for people living with MSA, a rare and devastating neurodegenerative disorder, are urgently needed as there are no treatments available that impact disease progression.Emrusolmin is a small molecule that targets the alpha synuclein protein, which is believed to be pivotally invol...
Teva to Present at Morgan Stanley Global Healthcare Conference and Ban...
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September TEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in September as follows: Morgan Stanley 23rd Annual Global Healthcare ConferenceTuesday, September 9, 2025, at 8:30 A.M. ET BofA Global Healthcare Conference 2025 (London)Wednesday, September 24, 2025, at 9:00 A.M. ...
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutid...
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market.This approval and launch add to Teva’s continued commitment to its complex generic medicine portfolio as part of its Pivot to Growth Strategy.Liraglutide injection is indicated for adults with obesity or overweight (excess weight) who also have weight related medical problems, and pediatric patients (12-17 year...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.